Virological and Serological Characterisation of SARS-CoV-2 Infections Diagnosed After mRNA BNT162b2 Vaccination Between December 2020 and March 2021.
COVID-19
Italy
SARS-CoV-2
breakthrough infection
neutralising antibodies
vaccine
viral variants
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
11
2021
accepted:
22
12
2021
entrez:
7
2
2022
pubmed:
8
2
2022
medline:
8
2
2022
Statut:
epublish
Résumé
Vaccines for coronavirus disease 2019 (COVID-19) are proving to be very effective in preventing severe illness; however, although rare, post-vaccine infections have been reported. The present study focuses on virological and serological features of 94 infections that occurred in Lazio Region (Central Italy) between 27 December 2020, and 30 March 2021, after one or two doses of mRNA BNT162b2 vaccine. We evaluated clinical features, virological (viral load; viral infectiousness; genomic characterisation), and serological (anti-nucleoprotein Ig; anti-Spike RBD IgG; neutralising antibodies, nAb) characteristics of 94 post-vaccine infections at the time of diagnosis. Nasopharyngeal swabs (NPSs) and serum samples were collected in the framework of the surveillance activities on SARS-CoV-2 variants established in Lazio Region (Central Italy) and analysed at the National Institute for Infectious Diseases "L. Spallanzani" in Rome. The majority (92.6%) of the post-vaccine infections showed pauci/asymptomatic or mild clinical course, with symptoms and hospitalisation rate significantly less frequent in patients infected after full vaccination course as compared to patients who received a single dose vaccine. Although differences were not statistically significant, viral loads and isolation rates were lower in NPSs from patients infected after receiving two vaccine doses as compared to patients with one dose. Most cases (84%) had nAb in serum at the time of infection diagnosis, which is a sub-group of vaccinees, were found similarly able to neutralise Alpha and Gamma variants. Asymptomatic individuals showed higher nAb titres as compared to symptomatic cases (median titre: 1:120 vs. 1:40, respectively). Finally, the proportion of post-vaccine infections attributed either to Alpha and Gamma variants was similar to the proportion observed in the contemporary unvaccinated population in the Lazio region, and mutational analysis did not reveal enrichment of a defined set of Spike protein substitutions depending on the vaccination status. Our study conducted using real-life data, emphasised the importance of monitoring vaccine breakthrough infections, through the characterisation of virological, immunological, and clinical features associated with these events, in order to tune prevention measures in the next phase of the COVID-19 pandemic.
Sections du résumé
BACKGROUND
BACKGROUND
Vaccines for coronavirus disease 2019 (COVID-19) are proving to be very effective in preventing severe illness; however, although rare, post-vaccine infections have been reported. The present study focuses on virological and serological features of 94 infections that occurred in Lazio Region (Central Italy) between 27 December 2020, and 30 March 2021, after one or two doses of mRNA BNT162b2 vaccine.
METHODS
METHODS
We evaluated clinical features, virological (viral load; viral infectiousness; genomic characterisation), and serological (anti-nucleoprotein Ig; anti-Spike RBD IgG; neutralising antibodies, nAb) characteristics of 94 post-vaccine infections at the time of diagnosis. Nasopharyngeal swabs (NPSs) and serum samples were collected in the framework of the surveillance activities on SARS-CoV-2 variants established in Lazio Region (Central Italy) and analysed at the National Institute for Infectious Diseases "L. Spallanzani" in Rome.
RESULTS
RESULTS
The majority (92.6%) of the post-vaccine infections showed pauci/asymptomatic or mild clinical course, with symptoms and hospitalisation rate significantly less frequent in patients infected after full vaccination course as compared to patients who received a single dose vaccine. Although differences were not statistically significant, viral loads and isolation rates were lower in NPSs from patients infected after receiving two vaccine doses as compared to patients with one dose. Most cases (84%) had nAb in serum at the time of infection diagnosis, which is a sub-group of vaccinees, were found similarly able to neutralise Alpha and Gamma variants. Asymptomatic individuals showed higher nAb titres as compared to symptomatic cases (median titre: 1:120 vs. 1:40, respectively). Finally, the proportion of post-vaccine infections attributed either to Alpha and Gamma variants was similar to the proportion observed in the contemporary unvaccinated population in the Lazio region, and mutational analysis did not reveal enrichment of a defined set of Spike protein substitutions depending on the vaccination status.
CONCLUSION
CONCLUSIONS
Our study conducted using real-life data, emphasised the importance of monitoring vaccine breakthrough infections, through the characterisation of virological, immunological, and clinical features associated with these events, in order to tune prevention measures in the next phase of the COVID-19 pandemic.
Identifiants
pubmed: 35127770
doi: 10.3389/fmed.2021.815870
pmc: PMC8810639
doi:
Types de publication
Journal Article
Langues
eng
Pagination
815870Informations de copyright
Copyright © 2022 Colavita, Meschi, Gruber, Rueca, Vairo, Matusali, Lapa, Giombini, De Carli, Spaziante, Messina, Bonfiglio, Carletti, Lalle, Fabeni, Berno, Puro, Bartolini, Di Caro, Ippolito, Capobianchi and Castilletti.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Clin Infect Dis. 2022 Aug 24;75(1):e892-e894
pubmed: 34726700
MMWR Morb Mortal Wkly Rep. 2021 Apr 02;70(13):495-500
pubmed: 33793460
N Engl J Med. 2021 Jun 10;384(23):2212-2218
pubmed: 33882219
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Ann Intern Med. 2021 Dec;174(12):1770-1772
pubmed: 34662153
JAMA. 2021 Nov 23;326(20):2018-2020
pubmed: 34734985
JAMA Health Forum. 2021 Apr 1;2(4):e211195
pubmed: 36218817
Open Forum Infect Dis. 2020 Sep 02;7(10):ofaa403
pubmed: 33527081
Glob Chall. 2017 Jan 10;1(1):33-46
pubmed: 31565258
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
MMWR Morb Mortal Wkly Rep. 2021 Apr 30;70(17):632-638
pubmed: 33914721
BMC Genomics. 2016 Sep 05;17:708
pubmed: 27595578
Lancet Infect Dis. 2021 Nov;21(11):1485-1486
pubmed: 34506735
Cell. 2021 Apr 29;184(9):2384-2393.e12
pubmed: 33794143
Clin Microbiol Infect. 2022 Apr;28(4):612.e1-612.e7
pubmed: 34826623
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Nat Med. 2021 Aug;27(8):1379-1384
pubmed: 34127854
MMWR Morb Mortal Wkly Rep. 2021 May 28;70(21):792-793
pubmed: 34043615
Clin Infect Dis. 2022 Aug 24;75(1):e715-e725
pubmed: 34922338
SN Compr Clin Med. 2020;2(8):1069-1076
pubmed: 32838147
Nat Commun. 2021 Oct 15;12(1):6032
pubmed: 34654808
Lancet Infect Dis. 2022 Feb;22(2):e52-e58
pubmed: 34534512
Nat Med. 2021 May;27(5):790-792
pubmed: 33782619
Clin Microbiol Infect. 2021 Nov;27(11):1652-1657
pubmed: 34245907
N Engl J Med. 2021 Mar 17;384(15):1468-1470
pubmed: 33730471
PLoS One. 2020 Dec 31;15(12):e0244126
pubmed: 33382764
Viruses. 2021 Apr 10;13(4):
pubmed: 33920222
N Engl J Med. 2021 Oct 14;385(16):1474-1484
pubmed: 34320281
N Engl J Med. 2021 Oct 21;385(17):1629-1630
pubmed: 34587378
N Engl J Med. 2021 May 6;384(18):1774-1775
pubmed: 33755376
Clin Infect Dis. 2022 Aug 25;75(2):305-313
pubmed: 34410361
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Lancet. 2021 Mar 13;397(10278):952-954
pubmed: 33581803